Impact of prophylactic bilateral salpingo-oophorectomy in patients with colorectal cancer with peritoneal metastasis during cytoreductive surgery: dual-center cohort analysis.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
7 patients (26.
I · Intervention 중재 / 시술
CRS at two medical centres in southern China between 2017 and 2022
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
No significant differences were observed between the BSO and non-BSO groups in 2-year disease-free survival (P = 0.866) or overall survival (P = 0.557). [CONCLUSION] For patients with CRC with peritoneal metastasis and bilateral macroscopically normal ovaries, prophylactic BSO does not improve mid-term survival.
[BACKGROUND] Ovarian metastases are common in patients with colorectal cancer (CRC) with peritoneal metastases.
- p-value P = 0.048
- p-value P = 0.018
- 연구 설계 cohort study
APA
Xue X, Hong Z, et al. (2025). Impact of prophylactic bilateral salpingo-oophorectomy in patients with colorectal cancer with peritoneal metastasis during cytoreductive surgery: dual-center cohort analysis.. BJS open, 9(6). https://doi.org/10.1093/bjsopen/zraf145
MLA
Xue X, et al.. "Impact of prophylactic bilateral salpingo-oophorectomy in patients with colorectal cancer with peritoneal metastasis during cytoreductive surgery: dual-center cohort analysis.." BJS open, vol. 9, no. 6, 2025.
PMID
41324564 ↗
Abstract 한글 요약
[BACKGROUND] Ovarian metastases are common in patients with colorectal cancer (CRC) with peritoneal metastases. For patients with bilateral macroscopically normal ovaries, prophylactic bilateral salpingo-oophorectomy (BSO) remains controversial. This study assessed the survival benefit of prophylactic BSO during cytoreductive surgery (CRS).
[METHODS] This retrospective cohort study included patients with CRC with peritoneal metastases who underwent CRS at two medical centres in southern China between 2017 and 2022. Patients achieving complete CRS with bilateral macroscopically normal ovaries were included in the subsequent analysis and divided into BSO and non-BSO groups. The primary outcomes of interest were the rates of synchronous and metachronous ovarian metastases. Clinical and surgical variables, including peritoneal carcinoma index (PCI) scores, were analysed for their correlation with these outcomes. Disease-free survival and overall survival were analysed using the Kaplan-Meier method, and prognostic variables were analysed using multivariate logistic regression.
[RESULTS] Of 237 consecutive patients who underwent CRS, 94 had macroscopically normal ovaries. Of these, 69 (29.1%) underwent complete CRS and were divided into two groups: 26 who underwent prophylactic BSO and 43 with organ preservation. In the BSO group, 7 patients (26.9%) had occult synchronous ovarian metastases. In the non-BSO group, 13 patients (30.2%) developed metachronous ovarian metastases, with 10 of these patients undergoing secondary surgery for ovarian metastases. Both synchronous and metachronous ovarian metastases were significantly associated with a higher PCI (P = 0.048). Premenopausal status was independently associated with metachronous ovarian metastases (hazard ratio 6.281; 95% confidence interval 1.364 to 28.922; P = 0.018). No significant differences were observed between the BSO and non-BSO groups in 2-year disease-free survival (P = 0.866) or overall survival (P = 0.557).
[CONCLUSION] For patients with CRC with peritoneal metastasis and bilateral macroscopically normal ovaries, prophylactic BSO does not improve mid-term survival.
[METHODS] This retrospective cohort study included patients with CRC with peritoneal metastases who underwent CRS at two medical centres in southern China between 2017 and 2022. Patients achieving complete CRS with bilateral macroscopically normal ovaries were included in the subsequent analysis and divided into BSO and non-BSO groups. The primary outcomes of interest were the rates of synchronous and metachronous ovarian metastases. Clinical and surgical variables, including peritoneal carcinoma index (PCI) scores, were analysed for their correlation with these outcomes. Disease-free survival and overall survival were analysed using the Kaplan-Meier method, and prognostic variables were analysed using multivariate logistic regression.
[RESULTS] Of 237 consecutive patients who underwent CRS, 94 had macroscopically normal ovaries. Of these, 69 (29.1%) underwent complete CRS and were divided into two groups: 26 who underwent prophylactic BSO and 43 with organ preservation. In the BSO group, 7 patients (26.9%) had occult synchronous ovarian metastases. In the non-BSO group, 13 patients (30.2%) developed metachronous ovarian metastases, with 10 of these patients undergoing secondary surgery for ovarian metastases. Both synchronous and metachronous ovarian metastases were significantly associated with a higher PCI (P = 0.048). Premenopausal status was independently associated with metachronous ovarian metastases (hazard ratio 6.281; 95% confidence interval 1.364 to 28.922; P = 0.018). No significant differences were observed between the BSO and non-BSO groups in 2-year disease-free survival (P = 0.866) or overall survival (P = 0.557).
[CONCLUSION] For patients with CRC with peritoneal metastasis and bilateral macroscopically normal ovaries, prophylactic BSO does not improve mid-term survival.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Female
- Peritoneal Neoplasms
- Middle Aged
- Salpingo-oophorectomy
- Colorectal Neoplasms
- Retrospective Studies
- Cytoreduction Surgical Procedures
- Ovarian Neoplasms
- Aged
- China
- Adult
- Prophylactic Surgical Procedures
- bilateral salpingo-oophorectomy
- colorectal cancer
- cytoreductive surgery
- ovarian metastasis
같은 제1저자의 인용 많은 논문 (5)
- Kremen2 Promotes Colorectal Cancer Progression by Activating the EGFR/JAK2/STAT3 Signaling Pathway.
- Copper/iron-based intelligent nanoparticles self-amplify apoptosis/ferroptosis/cuproptosis in colorectal cancer.
- Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial.
- Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non-small cell lung cancer.
- Mechanisms underlying the promotion of papillary thyroid carcinoma occurrence and progression by Hashimoto's thyroiditis.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.